Associate Professor of Pharmaceutical Sciences
Director, Pharmaceutical Sciences Graduate Program
Graduate Coordinator, PhD Program in Pharmaceutical Sciences
Department of Biomedical & Nutritional Sciences
Zuckerberg College of Health Sciences
University of Massachusetts Lowell
3 Solomont Way, Suite 4
Lowell, MA 01854
Email: jonghan_kim@uml.edu
Jonghan Kim is Associate Professor in the Department of Biomedical and Nutritional Sciences at UMass Lowell. He received a BS degree in Pharmacy and an MS degree in Pharmacology from Seoul National University and a PhD degree in Pharmaceutical Sciences from Ohio State University with a study focused on protein transport. During his postdoc training at the Harvard School of Public Health, Boston, he investigated the transport mechanisms of iron and manganese through the alimentary and respiratory tracts and the brain. His research interests center around the characterization of pharmacokinetics, pharmacodynamics, and toxicology of drugs and biometals in the context of genetic susceptibility and nutrition.
Pharmacokinetics, Pharmacodynamics, Toxicology, Iron Disorders, Nanomedicine, Drug Delivery, Hematology, Neurodegeneration
Dr. Kim’s research interests center around the characterization of absorption, distribution, metabolism, and excretion of drugs and metals, including essential metals (iron, zinc, copper, and manganese) and toxic heavy metals (lead, cadmium, mercury, and arsenic), and drug/metal-induced toxicity in the context of environmental exposure and genetic susceptibility.
Using various transgenic animal models of iron deficiency and overload, we further evaluate the physiological relevance of genes and molecules responsible for impaired iron transport in the development and progression of hematological, cardiovascular, and neurodegenerative disorders – important and current public health issues.
In addition, we develop novel therapeutic strategies to prevent and treat iron-associated disorders, including 1) small molecule-based metal transport modulators, 2) nanoparticle-based detox therapy and 3) tissue-specific gene delivery and therapy.